Terminated PHASE1 NCT00400101

Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides

A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers

Sponsor: Swiss Tropical & Public Health Institute

Conditions Falciparum Malaria

Interventions Virosome-formulated synthetic peptides (malaria vaccine)

Updated 4 times since 2017 Last updated: Nov 15, 2006 Started: Nov 30, 2003 Completion: Oct 31, 2005

This PHASE1 trial investigates Falciparum Malaria and is currently terminated or withdrawn. Swiss Tropical & Public Health Institute leads this study, which shows 4 recorded versions since 2003 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE1
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE1
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE1
Jan 2017 — Jan 2021 [monthly]

Terminated PHASE1

First recorded

Nov 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Swiss Tropical & Public Health Institute

Data source: Swiss Tropical & Public Health Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.